Evidence map›Paper›PMID 35643280›Full record

Trial reportThe journal of allergy and clinical immunology. In practice2022

Peanut Oral Immunotherapy With or Without H

Derek K Chu, Tosha Freitag, Andrea Marrin, Tina D Walker, Ernie Avilla, Andeas Freitag, Paul Spill, Gary A Foster, Lehana Thabane, Manel Jordana and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. IgE and non-IgE-mediated pathways in anaphylaxis.Seminars in immunopathology · 2025
    Review
  5. The Role of Biologics in the Treatment of Food Allergy.The journal of allergy and clinical immunology. In practice · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Derek K ChuDepartment of Medicine, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada; The Research Institute of St Joe's Hamilton, Hamilton, ON, Canada. Electronic address: chudk@mcmaster.ca.
Tosha FreitagDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Andrea MarrinDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Tina D WalkerDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Ernie AvillaDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Andeas FreitagDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Paul SpillDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Gary A FosterDepartment of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada; The Research Institute of St Joe's Hamilton, Hamilton, ON, Canada.
Lehana ThabaneDepartment of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada; The Research Institute of St Joe's Hamilton, Hamilton, ON, Canada.
Manel JordanaDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
Susan WasermanDepartment of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: waserman@mcmaster.ca.
McMaster University · CAImpact · CASt. Joseph’s Healthcare Hamilton · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent forms of peanut oral immunotherapy (OIT) are associated with side effects, and there is a lack of evidence addressing how to mitigate them.

objectiveTo determine whether premedication with desloratadine and ranitidine results in fewer side effects during peanut OIT/desensitization.

methodsA total of 43 patients with peanut allergy (mean age, 7.6 ± 2.1 years, 37% females, 63% males, baseline eliciting dose, 33 ± 26 mg) were randomized to OIT with or without concomitant H

resultsAdverse reactions occurred more in the OIT groups compared with the double-placebo group (OIT with antihistamines vs double-placebo hazard ratio, 3.75 [95% CI, 2.79-4.72]; OIT with placebo antihistamines vs double-placebo, hazard ratio, 4.62 [95% CI, 3.61-5.62]). Patients given antihistamines cotreatment with OIT had a similar risk of adverse events compared with those who did not use antihistamines with OIT (hazard ratio, 1.23 [95% CI, 0.49-1.97]). OIT with and without antihistamines accelerated the incidence rate of adverse events compared with double-placebo (4.8 and 6.4 events per patient vs 3.5 per patient, incidence rate ratio, 2.49 [95% CI, 1.36-4.56] and 2.04 [95% CI, 1.01-4.15], respectively). Antihistamines pretreatment modestly reduced the frequency of moderate to severe adverse reactions among OIT-treated groups (1.9 per patient vs 4.2 per patient, incidence rate ratio, 0.46 [95% CI, 0.24-0.89]), primarily urticaria (0.6 vs 2.1 per patient) followed by abdominal pain (2.6 vs 4.2 per patient), but increased neuropsychiatric adverse events (primarily tiredness and sedation, 2.3 vs 0.7 per patient). Eliciting doses after treatment were similar in all groups. Quality of life improved similarly regardless of treatment with peanut OIT or placebo OIT.

conclusionsPeanut OIT with antihistamines modestly reduce the skin and gastrointestinal components of the high incidence of adverse reactions during OIT, and there are no clear differences in improvement in quality of life whether treated with OIT, OIT with antihistamines, or placebo OIT despite OIT being effective in inducing desensitization. Safer food allergy treatment approaches that importantly improve quality of life need to be proved in future robust randomized trials.

Indexed as

Peanut HypersensitivityAdministration, OralAllergensAnimalsArachisChildChild, PreschoolDesensitization, ImmunologicFemaleFishesHistamine AntagonistsHistamine H1 AntagonistsHumansImmunologic FactorsMalePremedicationAllergensHistamine AntagonistsHistamine H1 AntagonistsImmunologic FactorsAdverse eventsDesloratadineFood allergyH(1) and H(2) antihistamine premedicationNet benefitOral immunotherapy (OIT)Peanut allergyQuality of lifeRandomized controlled trials (RCTs)RanitidineSafety

Identifiers

PMID35643280
OpenAlexW4281478573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.